- Home
- STX vs GILD Comparison
STX vs GILD Comparison
Compare STX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | GILD |
|---|---|---|
| Founded | 1978 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 168.6B |
| IPO Year | 2002 | 2002 |
Fundamental Metrics
Financial Performance| Metric | STX | GILD |
|---|---|---|
| Price | $883.72 | $134.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 18 |
| Target Price | ★ $604.14 | $148.39 |
| AVG Volume (30 Days) | 3.6M | ★ 5.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | 0.46% | ★ 2.55% |
| EPS Growth | 328.48 | ★ 1684.21 |
| EPS | ★ 8.29 | 1.61 |
| Revenue | $7,384,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $27.73 | $4.68 |
| Revenue Next Year | $25.06 | $6.04 |
| P/E Ratio | $106.64 | ★ $84.64 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $124.63 | $105.69 |
| 52 Week High | $905.39 | $157.29 |
Technical Indicators
Market Signals| Indicator | STX | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 73.56 | 50.77 |
| Support Level | $364.17 | $128.33 |
| Resistance Level | N/A | $137.50 |
| Average True Range (ATR) | 46.52 | 3.23 |
| MACD | 0.25 | 0.63 |
| Stochastic Oscillator | 86.47 | 60.15 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).